Effect of bicyclol in abnormal liver function induced by chemotherapy in gynecologic tumors

doi:10.12092/j.issn.1009-2501.2026.08.009

Abstract

Abstract:

AIM: To explore the effect of bicyclol in preventing and treating abnormal liver function indexs, which induced by chemotherapy in gynecologic tumors. METHODS: A total of 40 patients with abnormal liver function indices induced by chemotherapy for gynecologic tumors were selected from 2020 to 2022. They were divided into the bicyclol treatment group and the glycyrrhizin treatment (oral diammonium glycyrrhizinate enteric-coated capsules or compound glycyrrhizin tablets). Compared the changes in liver function indexs to evaluate the effect and adverse reaction between the two groups. RESULTS: After chemotherapy, the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma- glutamyl transferase (GGT), alkaline phosphatase (ALP), total bilirubin (TBIL), and direct bilirubin (DBIL) elevated. Following hepatoprotective treatment, these indexs decreased in both groups. Bicyclol tables reduced ALT more significantly than glycyrrhizin group (P<0.05). There was not adverse reactions in either group. CONCLUSION: Oral glycyrrhizin and bicyclol tablets are both effective in alleviating abnormal liver function indices caused by chemotherapy in gynecologic tumors. Compared to oral glycyrrhizin, bicyclol tablets demonstrate a superior effect in reducing liver enzyme levels. Patients with significantly elevated liver enzyme levels should consider bicyclol tablets as the preferred treatment option.

Key words: bicyclol tablet, oral glycyrrhizin, gynecologic tumor chemotherapy, abnormal liver function index

CLC Number:

R737

Tingting LIU, Mengxue HU, Yaru LIU, Chong YE, Quan XIA. Effect of bicyclol in abnormal liver function induced by chemotherapy in gynecologic tumors[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(8): 1085-1090.

Figures/Tables 7

References 20

1	杨钦磊, 韩秋惠, 魏小娟. 紫杉醇脂质体与紫杉醇注射液治疗晚期卵巢癌的疗效及安全性比较[J]. 临床合理用药, 2024, 17 (1): 31- 34.
2	Li M, Luo Q, Tao Y, et al. Pharmacotherapies for drug-induced liver injury: a current literature review[J]. Front Pharmacol, 2022, 12, 806249. doi: 10.3389/fphar.2021.806249
3	马世武, 刘成海, 刘晓琰, 等. 中国药物性肝损伤诊治指南 (2023年版)[J]. 胃肠病学, 2023, 28 (7): 397- 431.
4	Andrade RJ, Chalasani N, Björnsson ES, et al. Drug-induced liver injury[J]. Nat Rev Dis Primers, 2019, 5 (1): 58. doi: 10.1038/s41572-019-0105-0
5	陈永芳. 双环醇对抗结核药物所致肝损伤的临床分析[J]. 北方药学, 2018, 15 (12): 68- 69.
6	Li X, Tang J, Mao Y. Incidence and risk factors of drug-induced liver injury[J]. Liver Int, 2022, 42 (9): 1999- 2014. doi: 10.1111/liv.15262
7	邹红, 祁硕, 李丹丹, 等. 基于肝脏药物代谢酶CYP450表达探讨鸦胆子苦醇对裸鼠的肝毒性研究[J]. 中国临床药理学与治疗学, 2025, 30 (8): 1049- 1057.
8	张腾. 乱用药物的恶果—急性肝衰竭[J]. 食品与健康, 2024, 36 (1): 32- 33.
9	陆雨佳, 区可滢, 马越洋, 等. UGT1A1多态性与UGT1A1抑制药物相关药物性肝损伤的关系[J]. 实用医学杂志, 2025, 41 (4): 588- 593.
10	Chen K, Yang R, Shen FQ, et al. Advances in pharmacological activities and mechanisms of glycyrrhizic acid[J]. Curr Med Che, 2020, 27 (36): 6219- 6243. doi: 10.2174/0929867325666191011115407
11	Huo X, Meng X, Zhang J, et al. Hepatoprotective effect of different combinations of 18α-and 18β-Glycyrrhizic acid against CCl₄-induced liver injury in rats[J]. Biomed Pharmacother, 2020, 122, 109354. doi: 10.1016/j.biopha.2019.109354
12	谢雯, 于乐成. 双环醇临床应用专家共识—2020版[J]. 中华实验和临床感染病杂志(电子版), 2020, 14 (3): 177- 185.
13	Zhao T, Mao L, Yu Z, et al. Therapeutic potential of bicyclol in liver diseases: Lessons from a synthetic drug based on herbal derivative in traditional Chinese medicine[J]. Int Immunopharmacol, 2021, 91, 107308. doi: 10.1016/j.intimp.2020.107308
14	曾乌查, 林学德, 张志锋, 等. 双环醇片防治肿瘤化疗药物性肝损害的研究[J]. 中国当代医药, 2011, 18 (17): 5- 6.
15	佟欣, 樊华. 双环醇治疗胃癌化疗所致肝损伤患者肝功能指标的变化[J]. 实用肝脏病杂志, 2018, 21 (4): 625- 626.
16	葛蓉, 王建宁. 探讨应用双环醇治疗胃癌化疗所致肝损伤患者的效果[J]. 心理月刊, 2019, 14 (23): 196.
17	唐武兵, 杨文, 伍楚蓉, 等. 双环醇片在乳腺癌化疗中防治肝损害的临床研究[J]. 广东医学, 2014, 35 (17): 2753- 2756.
18	陈丽君, 方伟. 双环醇抗脓毒症诱导的小鼠暴发性肝炎作用及机制研究[J]. 中国临床药理学与治疗学, 2024, 29 (11): 1249- 1259.
19	刘宁, 李芳芳, 张丹, 等. 双环醇抗炎作用机制研究[J]. 中国药理学与毒理学杂志, 2016, 30 (10): 1031- 1032.
20	李虎, 李健蕊, 刘楠楠, 等. 双环醇通过抑制线粒体凋亡途径缓解TNF-α/D-GalN诱导的爆发性肝损伤[J]. 中国药理学通报, 2021, 37 (4): 478- 484.

Groups	n	Age (years)	Weight (kg)	Course (years)
Dicyclol	20	54.20±10.59	59.55±10.70	1.50±1.74
Glycyrrhizin	20	49.35±8.96	61.99±12.37	1.40±1.64
t	-	1.5640	0.6672	0.1893
P	-	0.1262	0.5087	0.8509

Groups	n	Age (years)	Weight (kg)	Course (years)
Dicyclol	20	54.20±10.59	59.55±10.70	1.50±1.74
Glycyrrhizin	20	49.35±8.96	61.99±12.37	1.40±1.64
t	-	1.5640	0.6672	0.1893
P	-	0.1262	0.5087	0.8509

Groups	n	ALT (U/L)	AST (U/L)	GGT (U/L)	ALP (U/L)	TBIL (μmol/L)	DBIL (μmol/L)
Dicyclol	20	24.35±12.65	25.85±11.70	49.85±68.48	115.60±110.73	11.15±4.01	2.12±0.96
Glycyrrhizin	20	28.45±23.46	30.80±21.89	42.50±30.20	174.05±306.00	13.10±10.48	3.09±5.20
t	-	0.6879	0.8919	0.4392	0.8033	0.7772	0.8204
P	-	0.4957	0.3781	0.6630	0.4268	0.4419	0.4171

Groups	n	ALT (U/L)	AST (U/L)	GGT (U/L)	ALP (U/L)	TBIL (μmol/L)	DBIL (μmol/L)
Dicyclol	20	24.35±12.65	25.85±11.70	49.85±68.48	115.60±110.73	11.15±4.01	2.12±0.96
Glycyrrhizin	20	28.45±23.46	30.80±21.89	42.50±30.20	174.05±306.00	13.10±10.48	3.09±5.20
t	-	0.6879	0.8919	0.4392	0.8033	0.7772	0.8204
P	-	0.4957	0.3781	0.6630	0.4268	0.4419	0.4171

Groups	n	ALT (U/L)	AST (U/L)	GGT (U/L)	ALP (U/L)	TBIL (μmol/L)	DBIL (μmol/L)
Dicyclol	20	50.00±24.39	46.15±24.71	87.84±81.95	145.84±135.55	12.68±4.95	2.52±1.14
Glycyrrhizin	20	70.70±54.76	63.05±34.43	67.85±57.64	169.05±263.23	13.14±7.10	2.76±2.05
t	-	1.5440	1.7830	0.8923	0.3506	0.2377	0.4576
P	-	0.1308	0.0825	0.3779	0.7278	0.8134	0.6499